Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022;12(2):571-584.
doi: 10.3233/JPD-212866.

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes

Emil Ygland Rödström  1   2 , Niklas Mattsson-Carlgren  2   3   4 , Shorena Janelidze  4 , Oskar Hansson  3   5 , Andreas Puschmann  1   2
Affiliations
Observational Study

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes

Emil Ygland Rödström et al. J Parkinsons Dis. 2022.

Abstract

Background: Biochemical and clinical biomarkers correlate with progression rate and disease severity in Parkinson's disease (PD) but are not sufficiently studied in late PD.

Objective: To examine how serum neurofilament light chain (S-NfL) alone or combined with clinical classifications predicts PD outcome in later disease stages.

Methods: Eighty-five patients with 7.9±5.1 years of PD duration were included in an observational cohort. Clinical scores were obtained at two separate examinations 8.2±2.0 years apart. S-NfL levels were determined with single molecule array (SiMoA). Five predefined disease progression milestones were assessed. After affirming combination potential of S-NfL and either of two clinical classifications, three combined models were constructed based on these factors and age at onset in different combinations.

Results: S-NfL levels showed significant hazard ratios for four out of five disease progression milestones: walking-aid usage (HR 3.5; 95% CI 1.4-8.5), nursing home living (5.1; 2.1-12.5), motor end-stage (6.2; 2.1-17.8), and death (4.1; 1.7-9.7). Higher S-NfL levels were associated with lower ability in activities of daily living and poorer cognition at baseline and/or at follow-up. Combined models showed significantly improved area under receiver operating characteristic curves (0.77-0.91) compared to S-NfL levels alone (0.68-0.71) for predicting the five disease milestones.

Conclusion: S-NfL levels stratified patients according to their likelihood to reach clinically relevant progression milestones during this long-term observational study. S-NfL alone reflected motor and social outcomes in later stages of PD. Combining S-NfL with clinical factors was possible and exploratory combined models improved prognostic accuracy.

Keywords: Parkinson’s disease; biomarkers; dementia; mortality; neurofilament proteins; prognosis.

PubMed Disclaimer

Conflict of interest statement

OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. AP has received reimbursement from Elsevier Ltd. for work as Associate Editor for the journal Parkinsonism & Related Disorders. All other authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow chart. Flow chart of patient inclusion and exclusion into the study at baseline and re-examination. Number of blood samples readily analyzed for serum neurofilament light chain levels in parenthesis. Adapted from [24].
Fig. 2
Fig. 2
Survival curves for studied milestones of disease progression. Survival curves of Kaplan-Meier estimates for individuals below or above cohort median of serum neurofilament light chain levels. Graphs show time from the baseline examination to: A) walking-aid usage, B) nursing-home residency, C) Hoehn and Yahr stage 5, D) dementia development, E) death. Log rank test results in the lower left part of the corresponding graph. Number of individuals remaining to be observed at each 2-year step showed below each graph. S-NfL, serum neurofilament light chain.
Fig. 3
Fig. 3
ROC-curves for S-NfL. Receiver operator characteristics (ROC) curves for having reached the five different milestones of disease progression at any point during the study period. A) walking-aid usage, B) nursing-home residency, C) Hoehn and Yahr stage 5, D) dementia development, E) death. S-NfL, serum neurofilament light chain levels (pg/ml); S-NfL + AaO, combined model based on tertiles of age at onset and S-NfL levels; S-NfL + SCS + AaO combined model based on simplified clinical subtype combined with tertiles of age at onset and S-NfL levels; S-NfL + PIGD score + AaO, combined model based on tertiles of postural instability and gait disorder score, age at onset and S-NfL levels.
See this image and copyright information in PMC

References

    1. Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49, 328–338. - PubMed
    1. Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Koks S, Kruger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM (2015) Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. Parkinsonism Relat Disord 21, 675–682. - PubMed
    1. Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71, 499–504. - PubMed
    1. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18, 573–586. - PubMed
    1. Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM (2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89, 1279–1287. - PMC - PubMed

Publication types